Clinical Trial Update: A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating BNT111 in combination with cemiplimab, or as single agents, in patients with advanced or unresectable melanoma that progressed after …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• BNT111
• Libtayo (cemiplimab)

Snippet

Sponsor: BioNTech SE | Conditions: Melanoma Stage III, Melanoma Stage IV | Phase 2 | Status: COMPLETED | Results posted: 2025-12-15